About Chemosyn
Chemosyn is a Healthcare company based in India founded in 1961. It operates as a pharmaceutical manufacturing and distribution of medicines in India. Its Indian entity Chemosyn Limited reported revenue of ₹24.95 Cr. Chemosyn offers products and services including Analgesics and Antipyretics and Cardiovascular Medicines. Its focus areas include Pharmaceuticals, Medicine Manufacturing, Drug Production and Distribution and Marketing.
Company details
Chemosyn is noted for its pharmaceutical production and marketing, which has evolved beyond traditional methods since 1961. High-end technology is employed in the manufacture of medicines to treat diverse health ailments, including analgesics, cardiovascular drugs, and phyto pharmaceuticals. A pan-India presence is maintained in regions like Mumbai, Ahmedabad, and Vapi, where products are distributed to meet public health needs. Studies on offerings such as C23C tablets are conducted to improve health parameters, ensuring reliable solutions are available for various disorders.
- Headquarters India
- SectorsHealthcare
- Email••••••••
- Social LinkedIn Facebook Instagram
- Legal Name Chemosyn Limited
- Date of Incorporation 27 Mar, 1962
- Jurisdiction Mumbai, Maharashtra, India
- Annual Revenue₹24.95 Cr
FY 2025 · -22% YoY
- Net Loss-₹19,214
FY 2025 · 0% margin
- EBITDA₹73.7 Lakh
FY 2025 · 3% margin
Associated legal entities of Chemosyn
Chemosyn operates through Chemosyn Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Chemosyn Limited CIN U24239MH1962PLC012310 | Active | 27 Mar 1962 | Mumbai, Maharashtra | ₹25.0 Cr | – | 3 | View details |
Products & Services of Chemosyn
Chemosyn offers a comprehensive portfolio of products and services, including Analgesics and Antipyretics and Cardiovascular Medicines.
Medicines are manufactured for pain relief and fever reduction to address common health ailments.
Products are provided for treating heart-related conditions as part of a broader range of pharmaceutical offerings.
Board of directors of Chemosyn Limited (Chemosyn)
Chemosyn Limited is the primary company behind Chemosyn. The board of Chemosyn Limited currently have 3 directors; the longest-serving is Aanal Samir Shah, appointed in 2006. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Aanal Samir Shah DIN 00120337 | Whole-time director | 18 Jul 2006 | 20 yrs 3 mo | Chemosyn Limited |
| Kanhai Samir Shah DIN 00120267 | Managing Director | 13 Dec 2007 | 18 yrs 10 mo | Chemosyn Limited |
| Madhav Samir Shah DIN 00532880 | Director | 13 Dec 2007 | 18 yrs 10 mo | Chemosyn Limited |
Financials of Chemosyn
Figures of Chemosyn Limited, the primary company behind Chemosyn, for FY 2025. Revenue was ₹24.95 Cr (-22% year on year). Net loss was -₹19,214 (0% margin). EBITDA was ₹73.7 Lakh (3% margin). Revenue has grown at a compounded annual rate of -11% over three years and -9% over five years.
- ₹24.95 CrRevenue · FY 2025 · -22% YoY
- -₹19,214Net loss · 0% margin
- ₹73.7 LakhEBITDA · 3% margin
- ₹1.00 CrPaid-up capital
- -11%Revenue CAGR, 3 years
- -9%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Chemosyn Limited are on its company page.
Detailed financial statements for Chemosyn
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Chemosyn (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Chemosyn
Chemosyn was founded in 1961.
Chemosyn is headquartered in India.
The primary company behind Chemosyn, Chemosyn Limited, reported revenue of ₹24.95 Cr for FY 2025, down 22% year on year.
Chemosyn is noted for its pharmaceutical production and marketing, which has evolved beyond traditional methods since 1961. High-end technology is employed in the manufacture of medicines to treat diverse health ailments, including analgesics, cardiovascular drugs, and phyto pharmaceuticals. A pan-India presence is maintained in regions like Mumbai, Ahmedabad, and Vapi, where products are distributed to meet public health needs. Studies on offerings such as C23C tablets are conducted to improve health parameters, ensuring reliable solutions are available for various disorders.
Chemosyn offers Analgesics and Antipyretics and Cardiovascular Medicines.
Chemosyn operates through Chemosyn Limited.
The legal entities of Chemosyn currently have 3 directors, including Aanal Samir Shah, Kanhai Samir Shah, Madhav Samir Shah.